CLEVELAND, , Dec. 31, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity ...

SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, ...

Stem Health Plus’s unique approach integrates advanced research in stem cell biology with state-of-the-art medical practices. The company’s commitment to innovation is driven by the potential to not ...

The Amendment strengthens the Company’s capital structure and improves its near- term liquidity position, enhancing the Company’s ability to continue to drive adoption and utilization of optical ...

Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients ...

as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company ...

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients ...

Circular mRNA significantly increasing protein expression vs. linear mRNA ...

Woburn, MA, Dec. 31, 2024 (GLOBE NEWSWIRE) -- CellMosaic CEO Dr. Yumei Huang will host a live presentation and Q&A on January 7 at 2:00 PM EST to discuss how the company's breakthrough technology is ...

– Financing enables Vireo to fund investments in additional organic and acquisitive growth opportunities – MINNEAPOLIS, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") ...

Pet2DAO, our DAO Company was established in late 2022 and launched its token, PDAO, in early 2023. PDAO was launched as a utility token, integrating traditional corporate governance with innovative ...

Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuations Enrollment to be extended due to low influenza infection among ...